Welcome to Glucagon.com

• HOME AND SEARCH
• COVID-19, SARS-CoV-2 and Diabetes
• GLUCAGON
  • GLUCAGON
  • Glucagon receptor
  • Glucagon, Hypoglycemia and Counterregulation
  • Glucagon Receptor Antagonists
• GLP-1
  • GLP-1
  • GLP-1 and the alpha cell
  • GLP-1 therapy adverse events
  • GLP-1 and the b-cell
  • GLP-1, b-cell proliferation and differentiation and apoptosis
  • GLP-1 and islet transplantation
  • GLP-1 and insulin sensitivity
  • GLP-1 and gastric emptying
  • GLP-1 and the cardiovascular system
  • GLP-1 action in the CNS
  • GLP-1 and the portal signal
  • GLP-1 and food intake
  • GLP-1 actions independent of glucose homeostasis
  • GLP-1 receptor
  • GLP-1 Receptor Desensitization
  • GLP-1 actions and a second GLP-1 receptor
  • GLP-1R-/- mice
  • GLP-1 synthesis and secretion, and degradation
  • GLP-1 and hypoglycemia
  • GLP-1(9-36)amide
  • GLP-1 action in human subjects
  • GLP-1 ACTION IN NON-DIABETIC SUBJECTS
  • GLP-1 ACTION IN TYPE 2 DIABETES
  • GLP-1R agonists and human diabetes
  • Liraglutide
    • EXENATIDE (EXENDIN-4)
  • Exendin-4: Human Data
  • EXENATIDE ONCE WEEKLY
  • GLP-1 analogues and human diabetes
  • GLP-1 actions and a second GLP-1 receptor
  • albiglutide & dulaglutide
  • GLP-1 targets
  • Alternative GLP-1 delivery systems
  • glp-1, inflammation & immune function
• GLP-2
  • GLP-2
  • GLP-2 and Human Tumors
  • GLP-2 action
  • GLP-2 receptor
  • GLP-2 secretion and metabolism
  • GLP-2 structure and activity
  • DPP-4 and GLP-2
  • GLP-2 and intestinal disease
  • GLP-2 and the CNS
  • Essential GLP-2 action: Studies with antagonists
• Drucker Lab
  • Drucker Lab
  • Drucker Lab Research
  • Drucker Publications
  • Graduate Students and postdoctoral fellows
• DPP-4
  • DPP-4
  • DPP-4 and Diabetes
  • dpp-4 AND THE CARDIOVASCULAR SYSTEM
  • DPP-4 inhibitors: Clinical Data
  • SITAGLIPTIN
  • SAXAGLIPTIN, ALOGLIPTIN, LINAGLIPTIN
  • VILDAGLIPTIN
• • DPP-4 Loss of function models
  • DPP-4 and GLP-2
  • DPP-4 and immune function
• GIP
  • GIP
  • GIP Receptor
  • GIP-based Co-Agonists GIP Antagonists
  • GIP and Human Diabetes
• Glicentin
• Glucagon Gene
• Gut endocrine cells
  • Gut endocrine cells
  • GLUTag cells
  • Gut hormones and bariatric surgery
• Islet α-cells
• Links
• Oxyntomodulin
• Receptors
  • Receptors
  • GLP-1 receptor
  • Mice with a targeted mutation in the GLP-1 receptor
  • Glucagon receptor (GLU-R)
  • GLP-2 receptor
  • GIP Receptor
• Research Reagents
  • Research Reagents
  • GLUTag cells
  • Mice with a targeted mutation in the GLP-1 receptor
• The Incretin Effect
  • The Incretin Effect
  • GLP-1 synthesis and secretion, and degradation

the Web site devoted to the study of the glucagon-like peptides

This Web site is maintained by Dr. Daniel J. Drucker, Mount Sinai Hospital Lunenfeld-Tanenbaum Research InstituteUniversity of Toronto

@DanielJDrucker   

 

Glucagon-like peptide-1 receptor-based

therapeutics for metabolic liver disease

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Copyright © 2008 Glucagon.com
Last Updated: July 30, 2022